Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma-Reference-Cited by-同舟云学术

Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma

Published:2019-03-01 Issue:3 Volume:5 Page:351
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Hassan Raffit¹,Thomas Anish²,Nemunaitis John J.³,Patel Manish R.⁴,Bennouna Jaafar⁵,Chen Franklin L.⁶,Delord Jean-Pierre⁷,Dowlati Afshin⁸,Kochuparambil Samith T.⁹,Taylor Matthew H.¹⁰,Powderly John D.¹¹,Vaishampayan Ulka N.¹²,Verschraegen Claire¹³,Grote Hans Juergen¹⁴,von Heydebreck Anja¹⁴,Chin Kevin¹⁵,Gulley James L.¹⁶¹⁷

Affiliation:

1. Thoracic and GI Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland

2. Developmental Therapeutics Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland

3. Division of Hematology and Oncology, University of Toledo College of Medicine, Toledo, Ohio

4. Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota

5. Department of Pneumology, Thoracic Oncology Unit, University Hospital of Nantes, Nantes, France

6. Novant Health Oncology Specialists, Winston-Salem, North Carolina

7. Institut Universitaire du Cancer-Oncopole, Toulouse, France

8. Division of Hematology and Oncology, University Hospitals Case Medical Center, Case Western Reserve University, Cleveland, Ohio

9. Virginia Piper Cancer Institute, Minneapolis, Minnesota

10. Knight Cancer Institute, Oregon Health & Science University, Portland

11. Carolina BioOncology Institute, Huntersville, North Carolina

12. Karmanos Cancer Institute, Wayne State University, Detroit, Michigan

13. Division of Medical Oncology, Ohio State University Comprehensive Cancer Center, Columbus

14. Merck KGaA, Darmstadt, Germany

15. EMD Serono, Billerica, Massachusetts

16. Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland

17. Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Link

http:///jamaoncology/article-pdf/5/3/351/17345755/jamaoncology_hassan_2019_oi_180097.pdf

Reference34 articles.

1. The global burden of disease due to occupational carcinogens.;Driscoll;Am J Ind Med,2005

2. Life expectancy in pleural and peritoneal mesothelioma.;Shavelle;Lung Cancer Int,2017

3. Prognostic factors in the treatment of malignant pleural mesothelioma at a large tertiary referral center.;Flores;J Thorac Oncol,2007

4. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.;Vogelzang;J Clin Oncol,2003

5. Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma.;Ceresoli;Lung Cancer,2011

Cited by 132 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Newest therapeutic strategies impacting on rarest thoracic malignancies: The clinical case report of biphasic pleural mesothelioma;Heliyon;2024-08

2. Malignant Pleural Mesothelioma: Socioeconomic and Clinical Aspects;Current Cancer Therapy Reviews;2024-07-23

3. Advances in Immunotherapy for Malignant Pleural Mesothelioma: From Emerging Strategies to Translational Insights;Open Respiratory Archives;2024-07

4. Comparative efficacy of immune checkpoint inhibitors versus chemotherapy alone in diffuse pleural mesothelioma;Thoracic Cancer;2024-06-05

5. Clinical and pathological observation of conversion therapy for malignant peritoneal mesothelioma: a case report and literature review;Pathology and Oncology Research;2024-01-08